Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial.

Zobel EH, Wretlind A, Ripa RS, Rotbain Curovic V, von Scholten BJ, Suvitaival T, Hansen TW, Kjær A, Legido-Quigley C, Rossing P

BMJ open diabetes research & care1 Sept 2021Cited by 29 (Europe PMC)

PMID34518158PMCIDPMC8451300DOI10.1136/bmjdrc-2021-002395PepBankPUB-34518158

Read at source PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide for 26 weeks significantly decreased 21 plasma lipids versus placebo.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered 21 blood fats more than placebo did.
Peptide
Liraglutide
Outcome
DecreasePlasma lipids decreased (21 of 260)
Study
n = 102
Comparator
Placebo
Analysis
Secondary
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
Lipids decreased
21 lipids
liraglutide vs placebo
Source sentences
Summary
We observed significant decreases following liraglutide treatment compared with placebo in 21 lipids (p<7.1e-03) from the following lipid families: ceramides, hexocyl-ceramides, phosphatidylcholines, phosphatidylethanolamines and triglycerides.
2 context sentences(design, population, supporting numbers)
Summary · context
In a double-blind placebo-controlled trial, we randomized 102 persons with type 2 diabetes to liraglutide or placebo for 26 weeks.
Summary · context
The lipidome was measured using liquid-chromatography-coupled mass-spectrometry as a secondary end point in the study.
Report a problemFND-3451815801
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide significantly decreased plasma ceramides versus placebo.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered blood ceramides more than placebo did.
Peptide
Liraglutide
Outcome
DecreaseCeramides
Study
n = 102
Comparator
Placebo
Analysis
Secondary
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
We observed significant decreases following liraglutide treatment compared with placebo in 21 lipids (p<7.1e-03) from the following lipid families: ceramides, hexocyl-ceramides, phosphatidylcholines, phosphatidylethanolamines and triglycerides.
2 context sentences(design, population, supporting numbers)
Summary · context
In a double-blind placebo-controlled trial, we randomized 102 persons with type 2 diabetes to liraglutide or placebo for 26 weeks.
Summary · context
The lipidome was measured using liquid-chromatography-coupled mass-spectrometry as a secondary end point in the study.
Report a problemFND-3451815802
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide significantly decreased plasma hexosylceramides versus placebo.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered blood hexosylceramides more than placebo did.
Peptide
Liraglutide
Outcome
DecreaseHexosylceramides
Study
n = 102
Comparator
Placebo
Analysis
Secondary
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
We observed significant decreases following liraglutide treatment compared with placebo in 21 lipids (p<7.1e-03) from the following lipid families: ceramides, hexocyl-ceramides, phosphatidylcholines, phosphatidylethanolamines and triglycerides.
2 context sentences(design, population, supporting numbers)
Summary · context
In a double-blind placebo-controlled trial, we randomized 102 persons with type 2 diabetes to liraglutide or placebo for 26 weeks.
Summary · context
The lipidome was measured using liquid-chromatography-coupled mass-spectrometry as a secondary end point in the study.
Report a problemFND-3451815803
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide significantly decreased plasma phosphatidylcholines versus placebo.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered blood phosphatidylcholines more than placebo did.
Peptide
Liraglutide
Outcome
DecreasePhosphatidylcholines
Study
n = 102
Comparator
Placebo
Analysis
Secondary
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
We observed significant decreases following liraglutide treatment compared with placebo in 21 lipids (p<7.1e-03) from the following lipid families: ceramides, hexocyl-ceramides, phosphatidylcholines, phosphatidylethanolamines and triglycerides.
2 context sentences(design, population, supporting numbers)
Summary · context
In a double-blind placebo-controlled trial, we randomized 102 persons with type 2 diabetes to liraglutide or placebo for 26 weeks.
Summary · context
The lipidome was measured using liquid-chromatography-coupled mass-spectrometry as a secondary end point in the study.
Report a problemFND-3451815804
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide significantly decreased plasma phosphatidylethanolamines versus placebo.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered blood phosphatidylethanolamines more than placebo did.
Peptide
Liraglutide
Outcome
DecreasePhosphatidylethanolamines
Study
n = 102
Comparator
Placebo
Analysis
Secondary
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
We observed significant decreases following liraglutide treatment compared with placebo in 21 lipids (p<7.1e-03) from the following lipid families: ceramides, hexocyl-ceramides, phosphatidylcholines, phosphatidylethanolamines and triglycerides.
2 context sentences(design, population, supporting numbers)
Summary · context
In a double-blind placebo-controlled trial, we randomized 102 persons with type 2 diabetes to liraglutide or placebo for 26 weeks.
Summary · context
The lipidome was measured using liquid-chromatography-coupled mass-spectrometry as a secondary end point in the study.
Report a problemFND-3451815805
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide significantly decreased plasma triglycerides versus placebo.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered blood triglycerides more than placebo did.
Peptide
Liraglutide
Outcome
DecreaseTriglycerides
Study
n = 102
Comparator
Placebo
Analysis
Secondary
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
We observed significant decreases following liraglutide treatment compared with placebo in 21 lipids (p<7.1e-03) from the following lipid families: ceramides, hexocyl-ceramides, phosphatidylcholines, phosphatidylethanolamines and triglycerides.
2 context sentences(design, population, supporting numbers)
Summary · context
In a double-blind placebo-controlled trial, we randomized 102 persons with type 2 diabetes to liraglutide or placebo for 26 weeks.
Summary · context
The lipidome was measured using liquid-chromatography-coupled mass-spectrometry as a secondary end point in the study.
Report a problemFND-3451815806
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the liraglutide-related lipid decreases versus placebo were confirmed in adjusted models.
In plain wordsIn adults with type 2 diabetes, the lipid drops with liraglutide stayed clear after adjusting for other factors.
Peptide
Liraglutide
Outcome
DecreaseLipid decreases in covariate-adjusted models
Study
n = 102
Comparator
Placebo
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
We confirmed these findings in adjusted models (p≤0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
In a double-blind placebo-controlled trial, we randomized 102 persons with type 2 diabetes to liraglutide or placebo for 26 weeks.
Summary · context
The lipidome was measured using liquid-chromatography-coupled mass-spectrometry as a secondary end point in the study.
Report a problemFND-3451815807
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, individual lipids fell by 14% to 61% from baseline with liraglutide, compared with a 19% decrease to a 27% increase with placebo.
In plain wordsIn adults with type 2 diabetes, single blood fats fell 14% to 61% with liraglutide, versus a 19% fall to a 27% rise with placebo.
Peptide
Liraglutide
Outcome
DecreaseSize of lipid reduction from baseline
Study
n = 102
Comparator
Placebo
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
Lipid reduction from baseline
14 to 61%
liraglutide group
Source sentences
Summary
In the liraglutide-treated group, the individual lipids were reduced in the range of 14%-61% from baseline level, compared with 19% decrease to 27% increase from baseline level in the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
In a double-blind placebo-controlled trial, we randomized 102 persons with type 2 diabetes to liraglutide or placebo for 26 weeks.
Summary · context
The lipidome was measured using liquid-chromatography-coupled mass-spectrometry as a secondary end point in the study.
Report a problemFND-3451815808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT03449654

Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes

Steno Diabetes Center Copenhagenn = 10226 Oct 2017 to 16 Aug 2019

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 11 Jun 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.